PDCD1 and neoplasm: In this study, we aimed to determine the prognostic usefulness of post-treatment NLR, PLR, LIPI, and mGPS obtained at the 6th week of treatment to reveal a reliable, robust, inexpensive, and potentially tumour-agnostic post-treatment indicator for predicting the response to anti-PD-1 combined therapy.